Home › Lymphoma › Michigan › Ann Arbor
Lymphoma clinical trials in Ann Arbor, MI
5 studies for Lymphoma are looking for participants at sites in and around Ann Arbor (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
RecruitingPhase 1/2
- C S Mott Children's Hospital, Ann Arbor
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
RecruitingPhase 3
- University of Michigan Health System, Ann Arbor
DALY II USA/ MB-CART2019.1 for DLBCL
RecruitingPhase 2
- University of Michigan, Ann Arbor
Living Well With Lymphoma
Recruiting
- University of Michigan, Ann Arbor
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
RecruitingPhase 1
- University of Michigan, Ann Arbor
About Lymphoma
Lymphoma is a cancer affecting the immune system. Hodgkins Lymphoma and Non Hodgkins Lymphoma are types of lymphoma. Learn about symptoms and treatments.
More about Lymphoma on MedlinePlus
Lymphoma trials in other cities
- Houston, TX34 studies
- Boston, MA33 studies
- New York City, NY33 studies
- Washington, DC23 studies
- Baldwin Park, CA21 studies
- Chicago, IL20 studies
- Durham, NC17 studies
- St. Louis, MO15 studies
- Philadelphia, PA15 studies
- Cleveland, OH14 studies
- Edison, NJ12 studies
- Atlanta, GA12 studies
Other studies in Ann Arbor
- Prostate Cancer27 studies
- Breast Cancer26 studies
- Non-Small Cell Lung Cancer26 studies
- Cancer (all types)25 studies
- Colorectal Cancer23 studies
- Lung Cancer23 studies
- Heart Failure22 studies
- Acute Myeloid Leukemia17 studies
- Cardiovascular Disease16 studies
- Pancreatic Cancer14 studies
- Melanoma12 studies
- Kidney Cancer (Renal Cell Carcinoma)12 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.